Latest cancer nursing research literature

14 May 2020

Beaver, K., Williamson, S., Sutton, C. J., Gardner, A., & Martin-Hirsch, P. (2020). Endometrial cancer patients’ preferences for follow-up after treatment: A cross-sectional survey. European Journal of Oncology Nursing, 45.

Bourne, S. (2020). Chemotherapy in the workplace is popular with nurses and patients. Cancer Nursing Practice, 19(3), 18–19.

Corey, B., Smania, M. A., Spotts, H., & Andersen, M. (2020). Young Women With Breast Cancer: Treatment, care, and nursing implications. Clinical Journal of Oncology Nursing, 24(2), 139–147.

de Veer, A. J. E., Slev, V. N., Pasman, H. R., Verdonck-de Leeuw, I. M., Francke, A. L., & van Uden-Kraan, C. F. (2020). Assessment of a Structured Self-Management Support Intervention by Nurses for Patients With Incurable Cancer. Oncology Nursing Forum, 47(3), 305–317.

Good, M., Castro, K., Denicoff, A., Finnigan, S., Parreco, L., & Germain, D. S. (2020). National Cancer Institute: Restructuring to Support the Clinical Trials of the Future. Seminars in Oncology Nursing, 36(2).

Kessler, T. A. (2020). The Role of Cognitive Appraisal in Quality of Life Over Time in Patients With Cancer. Oncology Nursing Forum, 47(3), 292–304.

Linde, M. E., Braamse, A. M. J., Collette, E. H., Hoogendoorn, A. W., Snoek, F. J., Verheul, H. M. W., Dekker, J., & van Linde, M. E. (2020). Clinical assessment of emotions in patients with cancer: Diagnostic accuracy compared with two reference standards. Psycho-Oncology, 29(4), 775.

Otten, K. R., Staffileno, B. A., Mozer, M., & Maidlow, C. (2020). Mediterranean Diet: Outcomes from an education session among patients with cancer and nursing staff. Clinical Journal of Oncology Nursing, 24(2), 177–185.

Owens, O. L., Smith, K. N., Beer, J. M., Gallerani, D. G., & McDonnell, K. K. (2020). A Qualitative Cultural Sensitivity Assessment of the Breathe Easier Mobile Application for Lung Cancer Survivors and Their Families. Oncology Nursing Forum, 47(3), 331–341.

Portier, W. S. (2020). Cancer Clinical Trials: Implications for Oncology Nurses. Seminars in Oncology Nursing, 36(2).

Slev, V. N., Molenkamp, C. M., Eeltink, C. M., Roeline W Pasman, H., Verdonck-de Leeuw, I. M., Francke, A. L., & van Uden-Kraan, C. F. (2020). A nurse-led self-management support intervention for patients and informal caregivers facing incurable cancer: A feasibility study from the perspective of nurses. European Journal of Oncology Nursing, 45.

Wen-Pei, C., & Hsiu-Ju, J. (2020). Changes in fatigue in rectal cancer patients before and after therapy: a systematic review and meta-analysis. Supportive Care in Cancer, 28(6), 2513–2522.

NICE guidance updates

COVID-19 rapid guideline: children and young people who are immunocompromised (updated 21.5.20)

Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE

Our new draft guidance recommends atezolizumab for treating people with triple negative breast cancer that has spread to other parts of the body. Around 2,000 people in England have triple negative breast cancer, of which around 600 people would be eligible for treatment with atezolizumab with chemotherapy drug nab-paclitaxel.

Draft guidance recommends new treatment option for people with early breast cancer

Draft NICE guidance recommends trastuzumab emtansine (Kadcyla, Roche) as an option for some people with HER2-positive early breast cancer. Around 7,000 people diagnosed with breast cancer each year in England are HER2-positive

Treatment for small-cell lung cancer

We’ve recommended atezolizumab (Tecentriq, Roche) with carboplatin and etoposide as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC). Around 2,400 people in England have ES-SCLC, of whom around 1,200 people will be eligible for treatment with atezolizumab with carboplatin and etoposide.

Physical activity for people with metastatic bone disease – Guidance for healthcare professionals

This practical guidance (link below) may help when advising and supporting people with bone metastases about physical activity particularly if they are shielding or going out less in the current landscape of COVID.


Cancer patients to benefit from new histology independent treatment

Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF).


Patient group direction use in end of life care Patient Group Direction use in End of Life Care

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline  

CVC management: evidence round up from Cochrane.,W2J2,4EN77C,3Y6TW,1